Seven new phthalide compoundswith anti-i7elicobacter pylori activities were isolated from the basidiomycete Phanerochaete velutina CL6387, The two most potent phthalide compounds, CJ-12,954 and CJ-13,014, have MICs of 5 ng/ml. The structure-activity relationship shows that the presence of a spiroketal part in addition to the phthalide part, greatly enhances the activity. The phthalide compoundsappear to be specific for H. pylori, since they did not show antibacterial activities when tested against a panel of other microorganisms.
Gastric and duodenal ulcers affect a significant portion of the humanpopulation worldwide. Many recent studies have shown a relation between the presence of the microaerophilic Gram-negative bacterium Helicobacter pylori, which appears to live beneath the mucus layer of the stomach, and gastric and duodenal ulcers1'2*. Thus, therapy to eliminate H. pylori from the gastroduodenal tract would remove the root cause of gastric and duodenal ulcers. Current therapy typically relies upon co-administration of one or two broad-spectrumantibiotics combined with a proton pumpinhibitor or a bismuth salt. However,even triple therapy is not entirely successful in achieving long term eradication of H. pylori. Follow-up of patients cleared of H. pylori infection has shown that relapse (rather than reinfection) is a problem. Treatment of H. /?y/0n-associated gastric disorders with antibacterial agents given by conventional dosing regimens thus requires a prolonged course of therapy to be effectivel j2). However, long-term treatment with current therapies is not recommendedin view of side-effects, the build-up of drug resistance and, in particular, the inherent toxicity risk associated with a bismuth salt. Accordingly, there is a need for a safe and effective treatment with a compoundhaving excellent anti-H. pylori activity. In a screening program designed to discover such compounds from microbial secondary metabolites, the basidiomycete Phanerochaete velutina was found to produce new phthalide compounds with 2inti-Helicobacter pylori activity.
In this paper, we report the fermentation, 833 isolation, structural elucidation and biological activities of these phthalide compounds.
Producing Strain
The producing strain, the basidiomycete Phanerochaete velutina CL6387, was obtained from the Forest Fermentation Phanerochaete velutina CL6387 was maintained on plates of malt agar medium (malt extract 2.5% and agar 1.5%). A cell suspension from the plate was used to inoculate 50-ml tubes containing 10ml of Medium-1 (glucose 2%, malt extract 2%, yeast extract 1.8%, maltose 2.4% and agar 0.1%, pH 5.5). The tubes were incubated at 28°C on a shaker at 250rpm for 14 days.
The first seed culture (2 ml) was transferred to two 500-ml flasks containing 100ml of Medium-1. The flasks were incubated at 28°C for 7 days. These flasks were used to inoculate 7.5 ml each into twelve 500-ml flasks containing 150ml of Medium-1. These seed cultures in the 12 flasks were combined and used to inoculate 100ml into each of twelve 6-liter fermentation vessels containing 600 ml a singlet at 106.9 ppm and doublets at 98.6 and 97.3 ppm), which would be expected to be a l-carbonyl-2,4-dioxy-6-substituted benzene. These facts together with the benzene fragment from XHNMRsuppose 3,5-dimethoxyphthalide as a partial structure of 1. Also, the chemical shift of ketal carbon and two oxymethine fragments from XH NMRsuggest the l,6-dioxaspiro [4, 4] nonane system. Since the remaining elements are only methylenes with no heteroatom substitution, the whole structure is proposed to be 3,5-dimethoxyphthalide extended with a straight alkyl chain having a 1,6-dioxaspiro- [4, 4] nonane system at the end.
This structure was confirmed both by the comparison of spectral data with those of partially related compounds and by EI-MS analysis. Spirolaxine (8)4) has a structure closely related to that of the estimated 1. *H and 13C NMRdata for the phthalide and some part of extended aliphatic chain match each other, except for lack of one methoxy group in 8. UVabsorption maxima ofCJ-12,954 at 290.6, 257.6 and 217.4nm are also in good agreement with those of8. Comparisons of 13C NMRdata of the ketal carbon and two oxymethines in spiro-ketal ring should have 7-alkyl-2-methyll ,6-dioxaspiro [4, 4] nonane system (around 75, 114 and 80ppm), but not 1,6-dioxaspiro [4, 5] 
Structures of Phthalide Compounds3 to 7
According to NMRand UVspectra, all of the 5 other compounds 3 to 7 were suggested to have the same phthalide and aliphatic chain portions like that of 1, but to lack the spiroketal structure. The differences among these derivatives are the end parts of each aliphatic chain.
CJ-13,015 (3) has a molecular ion at m/z 418.2358 (calcd for C24H34O6, zl +0.5mmu). 13C NMRshowed 2 aliphatic ketones at 209.7 and 207.4ppm. One of them is an acetyl group with a methyl signal af29.9ppm. All the other signals except the phthalide part are sp 3 triplets. XH NMRspectra showed 2H triplet (2.42ppm) and 4H multiplet (2.67 ppm) assignable to a-positions ofcarbonyl groups, and the acetyl group (2.17ppm) which has to be at the end of the alkyl chain. As the 4H multiplet has no correlation to any other protons in the decoupling experiment, the end part of the alkyl chain was determined to be -CH2COCH2CH2COCH3, which was also supported by the sequential loss of fragments in the -12,954 (l) . Table 2 shows the effects of 1 on growth and survival 954 (ng/ml) A -0.3mmu), has 2-hydroxypropyl group at the end of the chain, which was determined both by decoupling experiment of this oxymethine and by the observation ofD2O exchangeable proton at 2.20ppm (1H, broad) in the *H NMRspectra.
EI-MS fragments at m/z 388 (M+ -H2O) and 362 (M+ -C2H5O+H) also supported the structure.
CJ-13,108 (7) has a molecular formula C24H36O5 (HREI-MS: m/z 404.2557, A -0.2mmu) and an acetyl group at the end like 3 from the XH and 13C NMR spectra. Becauseno other elements were left except the methylene chain, the structure was determined as 7.
Biological Properties
The helicobactericidal activities of the phthalide compounds are shown in Fig. 1 . In the antimicrobial assay using papaer disks, the most potent phthalides gave 15 mminhibition zones at 20 ng/disk. Noteworthy is that no antimicrobial activities were observed at a concentration of lOO jUg/disk when the phthalide compounds were tested against other microorganisms such as Bacillus stearothermophilus, Micrococcus luteus, Staphylococcus of H. pylori, indicating that MIC and MBCare similar (5 ng/ml) . This result confirmed that the phthalide compounds were bactericidal and not just bacteriostatic.
Discussion
To find H. pylori-specific antibacterial compounds which are expected to have less side-effects caused by disturbance of the normal gastro-intestinal microbial flora and not to induce drug resistance of non-target microorganisms, we pursued only those extracts which had anti-H. pylori activity, but were inactive against a panel of other Gram-positive and -negative bacteria. By this approach, we could efficiently eliminate many extracts having antibacterial activity caused by common antibiotics at the early stage of the screening program. As a result, wefound seven newphthalide compounds 1~7. The helicobactericidal activities of the phthalide compounds depend strongly on their structures (Fig. 1). Amongthese compounds, the spiroketal-containing 1 and 2 showed the most potent activities. The stereochemistry of the spiroketal part has no effect, but ring opening of the spiroketal to a diketone 3 reduces the potency 100-fold. The monoketone 7 is again 5-fold less potent, and after reduction to a hydroxy group 6, the activity is virtually lost.
Because of their specific anti-/f. pylori activity, the phthalide compounds might inhibit an H. pylori-specific target molecule which is not essential in the other tested microorganisms. It would therefore be interesting to examine the modeof action of the phthalide compounds further. Also, the information obtained from comparison of the phthalide compounds will be of great value during programs aiming at improvement of the in vivo pharmacological profile of the phthalide compounds.
The new compounds are related to spirolaxine and sporotricale4), originally discovered as plant growth inhibitors and recently also reported to have cholesterol lowering activity1 1). Spirolaxine has helicobactericidal activity similar to 1 and 2. These compounds may belong to the class of undecaketide derivatives such as phanerosporic acid12) and corticiolic acid13). There are many known antibiotics that contain a [5, 4] spiroketal, but the presence of a [4, 4] spiroketal is rare: some examples are an insect pheromone14'15) and a plant constituent16). We looked for [5, 4] 
